Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen ...

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, ...

Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by ...

European Commission approval enables 2 mg/kg Q4W pegunigalsidase alfa for stable, ERT-treated adults, extending infusion intervals from Q2W to Q4W to lessen cumulative treatment burden. Evidence ...

Italy’s Chiesi Group and Israel’s Protalix BioTherapeutics have announced that the European Commission (EC) has approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio (pegunigalsidase ...

The incidence of renal cell carcinoma among the included patients with Fabry disease was 15 times higher than in the general population. Patients with Fabry disease appear to have a higher incidence ...

Everyday Health’s team of board-certified physicians and health professionals contribute to the creation and review of content, ensuring that the information is useful, up to date, and accurate. Joy ...

Add Yahoo as a preferred source to see more of our stories on Google. uniQure's AAV gene therapy has displayed early efficacy in Fabry disease UniQure has ceased dosing in two cohorts in a Phase I/IIa ...

A 29-year-old Fabry patient finds relief with a specific cannabis blend, reducing excruciating pain within a month. Medical cannabis offers hope for Fabry disease patients with severe neuropathic pain ...

SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data ...

This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for ...